2025-12-18T22:03:44.826901+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: How severe is the cardiotoxicity? | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T22:04:02.349735+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: What's the outcome status? | Source: none | Retrieved: 0 | Clarification: True | Unknown: False | Safety: False
2025-12-18T22:04:15.633915+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: cardiotoxicity | Source: Pharma_Clinical_Trial_AllDrugs.xlsx, Pharma_Clinical_Trial_Notes.docx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T22:04:28.401682+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: Tell me about Nivolumab severe AEs | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T22:04:45.235246+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: What are the common adverse events for Trastuzumab? | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T22:05:19.919520+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: hat drugs are available for melanoma? | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T22:05:33.144336+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: Tell me about XYZ-Drug dosing | Source: none | Retrieved: 0 | Clarification: True | Unknown: False | Safety: False
2025-12-18T22:05:37.863392+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: XYZ | Source: none | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T22:06:14.745690+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: Provide dosage adjustment recommendations for renal impairment. | Source: Pharma_Clinical_Trial_AllDrugs.xlsx, Pharma_Clinical_Trial_Notes.docx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T22:07:16.840846+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: For any drug with severe AEs | Source: none | Retrieved: 0 | Clarification: True | Unknown: False | Safety: False
2025-12-18T22:07:29.035571+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: Osimertinib | Source: none | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T22:07:41.426541+0530 | INFO | Session: 06b6bc8a-5d7c-408b-9409-4ce02fcb1332 | User: Nivolumab | Source: Pharma_Clinical_Trial_AllDrugs.xlsx, Pharma_Clinical_Trial_Notes.docx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T22:07:53.140004+0530 | INFO | Session: a86c5956-fbd0-4ada-b3af-5b880aeb9983 | User: What AEs are reported for Pembrolizumab in melanoma? | Source: Pharma_Clinical_Trial_AllDrugs.xlsx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T22:08:07.093259+0530 | INFO | Session: a86c5956-fbd0-4ada-b3af-5b880aeb9983 | User: What label guidance is mentioned for cardiac monitoring? | Source: Pharma_Clinical_Trial_Notes.docx | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
2025-12-18T22:09:11.105685+0530 | INFO | Session: a86c5956-fbd0-4ada-b3af-5b880aeb9983 | User: Tell me about spaces | Source: none | Retrieved: 3 | Clarification: False | Unknown: False | Safety: False
